Join the Emtricitabine group to help and get support from people like you.
Emtricitabine News
FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy
FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 ...
FDA Approves Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) for HIV
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for...
FDA Approves New Combination Pill Stribild for HIV Treatment
August 27, 2012 – The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat...
U.S. Food and Drug Administration Approves Gilead Sciences' Complera, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug 10, 2011 - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera (emtricitabine/rilpivirine/tenofovir...